Literature DB >> 33658503

Integrative pan cancer analysis reveals epigenomic variation in cancer type and cell specific chromatin domains.

Lijin K Gopi1,2, Benjamin L Kidder3,4.   

Abstract

Epigenetic mechanisms contribute to the initiation and development of cancer, and epigenetic variation promotes dynamic gene expression patterns that facilitate tumor evolution and adaptation. While the NCI-60 panel represents a diverse set of human cancer cell lines that has been used to screen chemical compounds, a comprehensive epigenomic atlas of these cells has been lacking. Here, we report an integrative analysis of 60 human cancer epigenomes, representing a catalog of activating and repressive histone modifications. We identify genome-wide maps of canonical sharp and broad H3K4me3 domains at promoter regions of tumor suppressors, H3K27ac-marked conventional enhancers and super enhancers, and widespread inter-cancer and intra-cancer specific variability in H3K9me3 and H4K20me3-marked heterochromatin domains. Furthermore, we identify features of chromatin states, including chromatin state switching along chromosomes, correlation of histone modification density with genetic mutations, DNA methylation, enrichment of DNA binding motifs in regulatory regions, and gene activity and inactivity. These findings underscore the importance of integrating epigenomic maps with gene expression and genetic variation data to understand the molecular basis of human cancer. Our findings provide a resource for mining epigenomic maps of human cancer cells and for identifying epigenetic therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33658503     DOI: 10.1038/s41467-021-21707-1

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  91 in total

1.  Epigenetic dysregulation in cancer.

Authors:  Andrew G Muntean; Jay L Hess
Journal:  Am J Pathol       Date:  2009-08-28       Impact factor: 4.307

2.  The NCI-60 Methylome and Its Integration into CellMiner.

Authors:  William C Reinhold; Sudhir Varma; Margot Sunshine; Vinodh Rajapakse; Augustin Luna; Kurt W Kohn; Holly Stevenson; Yonghong Wang; Holger Heyn; Vanesa Nogales; Sebastian Moran; David J Goldstein; James H Doroshow; Paul S Meltzer; Manel Esteller; Yves Pommier
Journal:  Cancer Res       Date:  2016-12-06       Impact factor: 12.701

Review 3.  The NCI60 human tumour cell line anticancer drug screen.

Authors:  Robert H Shoemaker
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

Review 4.  The fundamental role of epigenetic events in cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Nat Rev Genet       Date:  2002-06       Impact factor: 53.242

Review 5.  Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host.

Authors:  Winston Timp; Andrew P Feinberg
Journal:  Nat Rev Cancer       Date:  2013-06-13       Impact factor: 60.716

6.  Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen.

Authors:  S F Stinson; M C Alley; W C Kopp; H H Fiebig; L A Mullendore; A F Pittman; S Kenney; J Keller; M R Boyd
Journal:  Anticancer Res       Date:  1992 Jul-Aug       Impact factor: 2.480

7.  Karyotypic complexity of the NCI-60 drug-screening panel.

Authors:  Anna V Roschke; Giovanni Tonon; Kristen S Gehlhaus; Nicolas McTyre; Kimberly J Bussey; Samir Lababidi; Dominic A Scudiero; John N Weinstein; Ilan R Kirsch
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701

8.  Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel.

Authors:  Lanlan Shen; Yutaka Kondo; Saira Ahmed; Yanis Boumber; Kazuo Konishi; Yi Guo; Xinli Chen; Jill N Vilaythong; Jean-Pierre J Issa
Journal:  Cancer Res       Date:  2007-12-01       Impact factor: 12.701

9.  Increased methylation variation in epigenetic domains across cancer types.

Authors:  Kasper Daniel Hansen; Winston Timp; Héctor Corrada Bravo; Sarven Sabunciyan; Benjamin Langmead; Oliver G McDonald; Bo Wen; Hao Wu; Yun Liu; Dinh Diep; Eirikur Briem; Kun Zhang; Rafael A Irizarry; Andrew P Feinberg
Journal:  Nat Genet       Date:  2011-06-26       Impact factor: 38.330

10.  High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.

Authors:  Sudhir Varma; Yves Pommier; Margot Sunshine; John N Weinstein; William C Reinhold
Journal:  PLoS One       Date:  2014-03-26       Impact factor: 3.240

View more
  11 in total

1.  H3K4 demethylase KDM5B regulates cancer cell identity and epigenetic plasticity.

Authors:  Runsheng He; Besa Xhabija; Lijin K Gopi; Jiji T Kurup; Zhishan Xu; Zhe Liu; Benjamin L Kidder
Journal:  Oncogene       Date:  2022-04-19       Impact factor: 8.756

2.  PHF13 epigenetically activates TGFβ driven epithelial to mesenchymal transition.

Authors:  Yating Sun; Dan Li; Hongmei Liu; Yongye Huang; Fanyu Meng; Jiahao Tang; Zhanjun Li; Wanhua Xie
Journal:  Cell Death Dis       Date:  2022-05-21       Impact factor: 9.685

Review 3.  Replication Stress, Genomic Instability, and Replication Timing: A Complex Relationship.

Authors:  Lina-Marie Briu; Chrystelle Maric; Jean-Charles Cadoret
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

4.  Differential enrichment of H3K9me3 at annotated satellite DNA repeats in human cell lines and during fetal development in mouse.

Authors:  Tanja Vojvoda Zeljko; Đurđica Ugarković; Željka Pezer
Journal:  Epigenetics Chromatin       Date:  2021-10-18       Impact factor: 4.954

5.  CpG Site-Specific Methylation-Modulated Divergent Expression of PRSS3 Transcript Variants Facilitates Nongenetic Intratumor Heterogeneity in Human Hepatocellular Carcinoma.

Authors:  Shuye Lin; Hanli Xu; Mengdi Pang; Xiaomeng Zhou; Yuanming Pan; Lishu Zhang; Xin Guan; Xiaoyue Wang; Bonan Lin; Rongmeng Tian; Keqiang Chen; Xiaochen Zhang; Zijiang Yang; Fengmin Ji; Yingying Huang; Wu Wei; Wanghua Gong; Jianke Ren; Ji Ming Wang; Mingzhou Guo; Jiaqiang Huang
Journal:  Front Oncol       Date:  2022-04-11       Impact factor: 5.738

6.  FOXK2 promotes ovarian cancer stemness by regulating the unfolded protein response pathway.

Authors:  Yaqi Zhang; Yinu Wang; Guangyuan Zhao; Edward J Tanner; Mazhar Adli; Daniela Matei
Journal:  J Clin Invest       Date:  2022-05-16       Impact factor: 19.456

7.  DNA Methylation-Specific Analysis of G Protein-Coupled Receptor-Related Genes in Pan-Cancer.

Authors:  Mengyan Zhang; Jiyun Zhao; Huili Dong; Wenhui Xue; Jie Xing; Ting Liu; Xiuwen Yu; Yue Gu; Baoqing Sun; Haibo Lu; Yan Zhang
Journal:  Genes (Basel)       Date:  2022-07-07       Impact factor: 4.141

Review 8.  Targeting the Transcriptome Through Globally Acting Components.

Authors:  Damien Parrello; Maria Vlasenok; Lincoln Kranz; Sergei Nechaev
Journal:  Front Genet       Date:  2021-09-16       Impact factor: 4.599

9.  Health influenced by genetics: A first comprehensive analysis of breast cancer high and moderate penetrance susceptibility genes in the Tunisian population.

Authors:  Maroua Boujemaa; Najah Mighri; Lotfi Chouchane; Mohamed Samir Boubaker; Sonia Abdelhak; Hamouda Boussen; Yosr Hamdi
Journal:  PLoS One       Date:  2022-03-25       Impact factor: 3.240

Review 10.  The dynamic broad epigenetic (H3K4me3, H3K27ac) domain as a mark of essential genes.

Authors:  Tasnim H Beacon; Geneviève P Delcuve; Camila López; Gino Nardocci; Igor Kovalchuk; Andre J van Wijnen; James R Davie
Journal:  Clin Epigenetics       Date:  2021-07-08       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.